Peptide Library

Peptide therapeutics database

Class, mechanism, sponsors, development stage, and key trials for peptide therapeutics in active biotech pipelines.

Stage

Class

Indication

9 of 9 peptides

Semaglutide

Ozempic · Wegovy · Rybelsus

Approved

GLP-1 receptor agonist

Type 2 Diabetes · Obesity · Cardiovascular Risk

Sponsor: Novo Nordisk

Reviewed 2026-07-15

Tirzepatide

Mounjaro · Zepbound

Approved

Dual GIP / GLP-1 receptor agonist

Type 2 Diabetes · Obesity

Sponsor: Eli Lilly

Reviewed 2026-07-15

Retatrutide

LY3437943

Phase 3

GIP / GLP-1 / glucagon triple agonist

Obesity · Type 2 Diabetes · MASH

Sponsor: Eli Lilly

Reviewed 2026-07-15

Survodutide

BI 456906

Phase 3

GLP-1 / glucagon dual agonist

Obesity · MASH

Sponsor: Zealand Pharma

Reviewed 2026-07-15

Cagrilintide

Phase 3

Long-acting amylin analog

Obesity

Sponsor: Novo Nordisk

Reviewed 2026-07-15

MariTide

AMG 133

Phase 2

GIPR antagonist / GLP-1 agonist peptide-antibody

Obesity

Sponsor: Amgen

Reviewed 2026-07-15

VK2735

Phase 2

Dual GLP-1 / GIP agonist

Obesity

Sponsor: Viking Therapeutics

Reviewed 2026-07-15

GSBR-1290

Phase 2

Oral small-molecule GLP-1

Obesity · Type 2 Diabetes

Sponsor: Structure Therapeutics

Reviewed 2026-07-15

Pemvidutide

ALT-801

Phase 2

GLP-1 / glucagon dual agonist

Obesity · MASH

Sponsor: Altimmune

Reviewed 2026-07-15